We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.50 | -0.41% | 1,583.50 | 1,582.50 | 1,583.00 | 1,595.50 | 1,580.00 | 1,593.00 | 5,931,081 | 16:35:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.22 | 65.15B |
From Apr 2019 to Apr 2024
LONDON--GlaxoSmithKline PLC (GSK.LN) Tuesday said the Salford lung study for chronic obstructive pulmonary disease, in collaboration with Innoviva Inc. (INVA), has had positive headline results.
The FTSE-100 healthcare company said the study showed that Relvar Ellipta achieved a superior reduction in exacerbations, compared with the usual care, in patients with COPD in an everyday clinical-practice setting. Study analyses are ongoing, the company said.
Shares at 1000 GMT up 5.50 pence, or 0.4%, at 1443.50 pence valuing the company at 70.32 billion pounds ($101.94 billion).
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga
(END) Dow Jones Newswires
May 24, 2016 06:27 ET (10:27 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
